Medical Device

AVRICORE HEALTH INC. (TSXV: AVCR) (the "Company" or “AVCR”) is pleased to announce that the Company is significantly expanding the number of Shoppers Drug Mart pharmacies offering its HealthTab point-of-care testing platform under a renewed Master Service Agreement (MSA) to up to 450 locations nation-wide.

In addition to Shoppers Drug Mart pharmacies, this new MSA and corresponding Statement of Work (SOW) provides for affiliated locations under the Loblaw family of brands, to utilize HealthTab upon request.

Announced in the summer of 2021 a signed MSA with Shoppers Drug Mart Inc. to pilot the HealthTab platform in 11 locations, allowing patients access to point-of-care blood screening and health-data management of potential risks for developing diabetes and cardiovascular conditions through the HealthTab-integrated Afinion 2™ analyzers by Abbott Rapid Diagnostics. After initial success, more locations in Ontario were added, as well as 5 locations in British Columbia.

“The results of the program so far have been fantastic and we’re very grateful to the hard-working pharmacy teams who have brought HealthTab to life,” said Hector Bremner, Avricore Health’s CEO. “Patient feedback showed that pharmacist’s capabilities are highly valued and having access to point-of-care data was seen as more supportive in their care, leading to better health outcomes.”

HealthTab has already been deployed in 104 Shoppers Drug Mart pharmacies across British Columbia, New Brunswick, Nova Scotia and Ontario. Additionally, the Company was honoured to have HealthTab placed in its first Alberta location, in the recently announced innovation in healthcare delivery, the pharmacist-led primary healthcare clinic in the Lethbridge Real Canadian Superstore®.

As of July 1st, 2022, the Government of Ontario brought into effect an expanded scope of practice for community pharmacists in the province. This includes limited prescribing for minor ailments, as well as the ability to perform certain point-of-care tests to assist patients with managing chronic disease. Approved tests include glucose, HbA1c and lipids, all of which HealthTab™ currently offers with the Abbott Afinion 2™.

The initial pilot demonstrated significant patient interest, and pharmacy teams have found they can easily incorporate these services into their practice. It is believed by all involved that with sustained communications support and market adoption, peak volumes are demonstrating a bright future for diagnostics in community pharmacy, and HealthTab as the most sophisticated and fully integrated solution that puts the patient at the centre of their own healthcare journey.

The pilot has also allowed for outreach to leading companies including third parties, such as employee benefits providers and contract research organizations (clinical trials), who have demonstrated interest in utilizing the network. This opens the door to collaboration and research opportunities, focused on lowering the cost of healthcare delivery and improving patient outcomes.

About HealthTab

HealthTab is a turnkey point-of-care testing solution that combines best-in-class point-of-care technologies with a secure, cloud-based platform for tackling pressing global health issues. With just a few drops of blood from a finger prick, the system generates lab-accurate results on the spot and data is reported in real time. The test menu includes up to 23 key biomarkers for screening and managing chronic diseases, such as diabetes and heart disease (e.g., HbA1c, Lipid Profile, eGFR). HealthTab has also recently added capabilities for bacterial and viral tests, such as strep and COVID-19.

The HealthTab network model is unlike anything in pharmacy today. It gives knowledgeable and trusted pharmacists a greater role in primary care delivery, while empowering patients to take more control of their health. It also reduces costs and waiting times and provides many potential revenue streams including equipment leasing & consumables, direct access testing, disease prevention & management programs, sponsored health programs, decentralized clinical trials, real world data (RWD) sets, and third-party app integration through API.

To find a location near you, please visit: healthtab.com/locations

HealthTab Market Fast Facts

  • Point-of-Care Testing Market to reach $50.6 Billion USD in 2025 (Source)
  • Glucose monitoring (diabetes related) to make up the largest growth within the sector. (Source)
  • Nearly 13.6 Million Canadians expected to diabetic or prediabetic by 2030, with many undiagnosed (Source)
  • Over 1 in 3 Americans, approximately 88 million people, have pre-diabetes (Source)
  • Close to 160,000 Canadians 20 years and older are diagnosed with heart disease each year, often it’s only after a heart attack they are diagnosed. (Source)
  • There are more that 10,000 pharmacies in Canada, 88,000 pharmacies in the US, nearly 12,000 in the UK.

About Avricore Health Inc.

Avricore Health Inc. (TSXV: AVCR) is a pharmacy service innovator focused on acquiring and developing early-stage technologies aimed at moving pharmacy forward. Through its flagship offering HealthTab™ (a wholly owned subsidiary), its mission is to make actionable health information more accessible to everyone by creating the world’s largest network of rapid testing devices in community pharmacies.

Contact:

Avricore Health Inc.
Hector Bremner, CEO 604-773-8943
info@avricorehealth.com
www.avricorehealth.com

Cautionary Note Regarding Forward-Looking Statements
Information in this press release that involves Avricore Health's expectations, plans, intentions or strategies regarding the future are forward-looking statements that are not facts and involve a number of risks and uncertainties. Avricore Health generally uses words such as "outlook," "will," "could," "would," "might," "remains," "to be," "plans," "believes," "may," "expects," "intends," "anticipates," "estimate," "future," "positioned," "potential," "project," "remain," "scheduled," "set to," "subject to," "upcoming," and similar expressions to help identify forward-looking statements.

In this press release, forward-looking statements include statements regarding: the completion of the placement and the expected timing thereof and the Company's expected use of proceeds from the placement; the unique features that the HealthTab™ platform offers to pharmacists and patients. Forward-looking statements reflect the then-current expectations, beliefs, assumptions, estimates and forecasts of Avricore Health's management. The forward-looking statements in this press release are based upon information available to Avricore Health as of the date of this press release. Forward-looking statements believed to be true when made may ultimately prove to be incorrect. These statements are not guarantees of the future performance of Avricore Health and are subject to a number of risks, uncertainties and other factors, some of which are beyond its control and may cause actual results to differ materially from current expectations, including without limitation: failure to meet regulatory requirements; changes in the market; potential downturns in economic conditions; and other risk factors described in Avricore's public filings. These forward-looking statements speak only as of the date on which they are made, and the Company undertakes no obligation to update them publicly to reflect new information or the occurrence of future events or circumstances, unless otherwise required to do so by law.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy

Click here to connect with Avricore Health (TSXV: AVCR) to receive an Investor Presentation

Source

AVCR:CA
avricore

Avricore Health


Keep reading...Show less
Avricore Health Announces CEO Update Call on Sept. 22, 2022

Avricore Health Announces CEO Update Call on Sept. 22, 2022

Avricore Health INC. (TSXV: AVCR) (the " Company " or " AVCR ") is excited to offer a live discussion on the Company's current activities and forward outlook as it executes a significant national scale-up of its pharmacy-based point-of-care platform, HealthTab.

"We're currently deploying a significant expansion of HealthTab systems and we're on track to achieve our revenue goals, as well as getting to cash flow positivity," said Avricore Health CEO, Hector Bremner. "It's an exciting time for the Company and we're looking forward to discussing the recent successes and future objectives."

Call Details:

September 22, 2022 @ 11:00am PT / 2:00pm ET via Zoom
Register here to receive login details: Investor@avricorehealth.com

Agenda:

The 60-minute call agenda will be as follows:
10min: Opening Remarks / Team Introductions
30Min: Overview Presentation and Update
20Min: Q&A

We're looking forward to seeing you there, please review our most recent investor presentation here: www.avricore.com

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Avricore Health Supports the Globe and Mail's Health Innovation Event

Avricore Health Supports the Globe and Mail's Health Innovation Event

Avricore Health INC. (TSXV: AVCR) (the " Company " or " AVCR ") was honoured to join the Globe and Mail's recent Health Care Innovation event, featuring leaders from various corners of the sector, including Company CEO, Hector Bremner.

"With about 40% of patients in Canada saying it's difficult to access a diagnostics test and nine million expressing difficulty in getting access to care, it's clear that the time is now to support more services in community pharmacy," says Avricore Health Inc. CEO, Hector Bremner. "HealthTab is already playing a significant role in supporting better services in pharmacy and we're going to continue to advocate for patients, and providers, so better outcomes for all are achieved."

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Avricore Health Reports Second-Quarter 2022 Results

Avricore Health Reports Second-Quarter 2022 Results

Avricore Health INC. (TSXV: AVCR) (the " Company " or " AVCR ") is pleased to provide this corporate update on the Company's Q2 results.

"We have now begun a new era for Healthtab™ and the Company as we expand Shoppers Drug Mart significantly over the coming weeks," said Hector Bremner, CEO of Avricore Health Inc. "We are now realizing our revenue targets and are on track to realize long-term profitability as we continue to successfully execute our plan."

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Avricore Grants Options

Avricore Grants Options

Avricore Health INC. (TSXV: AVCR) (the " Company " or " AVCR ") is pleased to announce that the Company's board of directors has approved the granting of stock options (the "Options") exercisable for a total of 2,725,000 common shares to its directors, officers, and consultants at an exercise price of CAD$0.15 per common share.

All Options were granted pursuant to the Company's stock option plan and are subject to the terms of the applicable grant agreements and the requirements of the TSX Venture Exchange.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Avricore Health Executing Growth Strategy - Summer 2022 Corporate Update

Avricore Health Executing Growth Strategy - Summer 2022 Corporate Update

Avricore Health INC. (TSXV: AVCR) (the " Company " or " AVCR ") is pleased to provide this corporate update on the Company's activities and progress in the first five months of 2022, as well as an outlook on the Company's objectives and expectations for the balance of the year.

"At the beginning of the year, we laid out a plan to expand our point-of-care testing platform in pharmacies across Canada and beyond and begin to generate more substantial revenues," said Hector Bremner, CEO of Avricore Health Inc. "Our progress towards those objectives has been significant, and we are very confident in our current client negotiations and planning."

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Knight Therapeutics Inc. places No. 22 on The Globe and Mail's fourth-annual ranking of Canada's Top Growing Companies

Knight Therapeutics Inc. (TSX:GUD) ("Knight" or "the Company") is pleased to announce it placed No. 22 on the 2022 Report on Business ranking of Canada's Top Growing Companies.

Canada's Top Growing Companies ranks Canadian companies on three-year revenue growth. Knight earned its spot with three-year growth of 1,850%.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Bausch Health and Glenmark Announce the approval of RYALTRIS® in Canada

- RYALTRIS ® (olopatadine hydrochloride and mometasone furoate nasal spray) treats moderate to severe seasonal allergic rhinitis (SAR) and associated ocular symptoms in adults, adolescents, and children aged 6 years and older

Bausch Health Companies Inc. (NYSE: BHC) (TSX: BHC) ("Bausch Health") and Glenmark Specialty S.A., a subsidiary of Glenmark Pharmaceuticals Ltd. (Glenmark), are pleased to announce that RYALTRIS ® (olopatadine hydrochloride and mometasone furoate nasal spray) has been approved by Health Canada for the symptomatic treatment of moderate to severe seasonal allergic rhinitis (SAR) and associated ocular symptoms in adults, adolescents, and children aged 6 years and older. 1

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less
person using high-tech ipad

Health is Wealth: The Point-of-Care Health Technology Model

To say the past few years have been a transformative time for healthcare would be putting it lightly.

Care providers all over the world continue to embrace the healthcare industry-wide digital transformation. We’ve seen the rise of transformative new technologies and the creation of new care models — all with one goal in mind: promoting and achieving better patient outcomes. Add to that the evolving role of pharmacies as a critical location for deploying point-of-care testing, and it’s clear why this innovative model is rapidly catching on.

Already a US$1.7 trillion business globally, the pharmacy sector is transitioning from a dispensation model of care to a more profitable, successful, patient-focused services model — supporting the growth of point-of-care technology in the process.

Keep reading...Show less

Medtronic announces closing of public offering of Euro3.5 billion of senior notes

Medtronic plc (the "Company") (NYSE: MDT) today announced that its wholly-owned subsidiary Medtronic Global Holdings S.C.A. ( "Medtronic Luxco") has closed a registered public offering (the "Offering") of €500,000,000 principal amount of 2.625% Senior Notes due 2025, €1,000,000,000 principal amount of 3.000% Senior Notes due 2028, €1,000,000,000 principal amount of 3.125% Senior Notes due 2031 and €1,000,000,000 principal amount of 3.375% Senior Notes due 2034 (collectively, the "Notes"). All of Medtronic Luxco's obligations under the Notes are fully and unconditionally guaranteed by the Company and Medtronic, Inc., a wholly-owned indirect subsidiary of Medtronic Luxco, on a senior unsecured basis.

The net proceeds from the Offering are approximately €3.47 billion, after deducting underwriting discounts and commissions and estimated expenses related to the Offering payable by Medtronic Luxco. The net proceeds of the Offering are expected to be used to repay at maturity Medtronic Luxco's outstanding 0.00% Senior Notes due 2022, 0.375% Senior Notes due 2023 and 0.00% Senior Notes due 2023 and for general corporate purposes. While Medtronic Luxco may elect at a later date to repay, redeem or repurchase such notes prior to maturity, it currently has no intention to repay, redeem or repurchase such notes prior to maturity.

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less

Danaher Schedules Third Quarter 2022 Earnings Conference Call

Danaher Corporation (NYSE: DHR) announced that it will webcast its quarterly earnings conference call for the third quarter 2022 on Thursday, October 20, 2022 beginning at 8:00 a.m. ET and lasting approximately 1 hour.

The call and an accompanying slide presentation will be webcast on the "Investors" section of Danaher's website, www.danaher.com , under the subheading "Events & Presentations." A replay of the webcast will be available shortly after the conclusion of the presentation and will remain available until the next quarterly earnings call.

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less

Medtronic receives FDA clearance for expanded indication of LINQ II insertable cardiac monitor for use in pediatric patients ages 2 and older

The LINQ II ICM is the first continuous, long-term cardiac monitor cleared by FDA for the pediatric patient population

- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced the LINQ II™ Insertable Cardiac Monitor (ICM) system is the first-and-only ICM to receive 510(k) clearance by the U.S. Food and Drug Administration (FDA) for use in pediatric patients over the age of 2 who have heart rhythm abnormalities and require long-term, continuous monitoring.

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×